ethazolastone has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
*Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Catapano, CV; D'Incalci, M; Erba, E; Filippeschi, S; Zucchetti, M | 1 |
1 other study(ies) available for ethazolastone and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
Topics: Blotting, Northern; Cell Cycle; Cell Differentiation; Dacarbazine; DNA Damage; DNA, Neoplasm; Flow Cytometry; Genes, ras; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylation; Proto-Oncogenes; Temozolomide; Tumor Cells, Cultured | 1989 |